These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 6831625)

  • 21. Comparative metabolism and elimination of adriamycin and 4'-epiadriamycin in the rat.
    Sweatman TW; Israel M
    Cancer Chemother Pharmacol; 1987; 19(3):201-6. PubMed ID: 3472675
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plasma pharmacokinetics of adriamycin and antipyrine and its relation to the therapeutic and toxic effects.
    Preiss R; Matthias M; Sohr R; Brockmann B; Hüller H
    Int J Clin Pharmacol Ther Toxicol; 1985 Apr; 23 Suppl 1():S79-88. PubMed ID: 3842695
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biopharmaceutical studies of spirobishexahydropyrimidine.
    Alam M; Ahmad M; Rasheed A; Ahmad A
    Indian J Exp Biol; 1992 Dec; 30(12):1181-3. PubMed ID: 1294482
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I clinical trial and pharmacokinetic evaluation of 4'-0-tetrahydropyranyladriamycin (THP-adriamycin).
    Raber MN; Newman RA; Lu K; Legha S; Gorski C; Benjamin RS; Krakoff IH
    Cancer Chemother Pharmacol; 1989; 23(5):311-5. PubMed ID: 2706737
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plasma pharmacokinetics of adriamycin and its metabolites in humans with normal hepatic and renal function.
    Benjamin RS; Riggs CE; Bachur NR
    Cancer Res; 1977 May; 37(5):1416-20. PubMed ID: 856462
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early phase pharmacokinetics of doxorubicin (adriamycin) in plasma of cancer patients during single- or multiple-drug therapy.
    Piazza E; Donelli MG; Broggini M; Sessa C; Natale N; Ottolenghi L; Marsoni S; Libretti A; Mangioni C; Morasca L
    Cancer Treat Rep; 1980; 64(8-9):845-54. PubMed ID: 7448822
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics and disposition of 4'-O-tetrahydropyranyladriamycin in mice by HPLC analysis.
    Iguchi H; Tone H; Ishikura T; Takeuchi T; Umezawa H
    Cancer Chemother Pharmacol; 1985; 15(2):132-40. PubMed ID: 4017162
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetic and tissue distribution changes of adriamycin and adriamycinol after intravenous administration of adriamycin to uranyl nitrate-induced acute renal failure rats.
    Lee HJ; Paik WH; Lee MG
    Res Commun Mol Pathol Pharmacol; 1996 Feb; 91(2):195-204. PubMed ID: 8832911
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influence of polysorbate 80 (Tween 80) and etoposide (VP-16-213) on the pharmacokinetics and urinary excretion of adriamycin and its metabolites in cancer patients.
    Cummings J; Forrest GJ; Cunningham D; Gilchrist NL; Soukop M
    Cancer Chemother Pharmacol; 1986; 17(1):80-4. PubMed ID: 3698181
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Might adriamycinol contribute to adriamycin-induced cardiotoxicity?
    Del Tacca M; Danesi R; Ducci M; Bernardini C; Romanini A
    Pharmacol Res Commun; 1985 Nov; 17(11):1073-84. PubMed ID: 4089011
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics of adriamycin in patients with breast cancer: correlation between pharmacokinetic parameters and clinical short-term response.
    Robert J; Illiadis A; Hoerni B; Cano JP; Durand M; Lagarde C
    Eur J Cancer Clin Oncol; 1982 Aug; 18(8):739-45. PubMed ID: 6891324
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics and toxicity of intraarterial adriamycin for hepatocellular carcinoma: effect of coadministration of lipiodol.
    Johnson PJ; Kalayci C; Dobbs N; Raby N; Metivier EM; Summers L; Harper P; Williams R
    J Hepatol; 1991 Jul; 13(1):120-7. PubMed ID: 1655867
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A pharmacokinetic study of adriamycin and 4'epi-adriamycin after simultaneous intra-arterial liver administration.
    Eksborg S; Andersson M; Domellöf L; Lönroth U
    Med Oncol Tumor Pharmacother; 1986; 3(2):105-10. PubMed ID: 3462442
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hepatobiliary metabolism and excretion of adriamycin and N-trifluoroacetyladriamycin-14-valerate in the rat.
    Israel M; Wilkinson PM; Pegg WJ; Frei E
    Cancer Res; 1978 Feb; 38(2):365-70. PubMed ID: 620407
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative pharmacokinetic study of adriamycin and 4'epi-adriamycin after their simultaneous intravenous administration.
    Eksborg S; Stendahl U; Lönroth U
    Eur J Clin Pharmacol; 1986; 30(5):629-31. PubMed ID: 3463510
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metabolism of adriamycin in hepatocytes isolated from the rat and the rabbit.
    Gewirtz DA; Yanovich S
    Biochem Pharmacol; 1987 Jun; 36(11):1793-8. PubMed ID: 3579974
    [TBL] [Abstract][Full Text] [Related]  

  • 37. General and cardiac toxicity of adriamycinol in rats.
    Danesi R; Del Tacca M; Della Torre P; Bernardini C
    Anticancer Res; 1986; 6(5):967-72. PubMed ID: 3800337
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Pharmacokinetic profile of high-dose doxorubicin administered during a 6 h intravenous infusion in breast cancer patients].
    Wihlm J; Limacher JM; Levêque D; Duclos B; Dufour P; Bergerat JP; Methlin G
    Bull Cancer; 1997 Jun; 84(6):603-8. PubMed ID: 9295863
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics of doxorubicin and its metabolite doxorubicinol in rabbits with induced acid and alkaline urine.
    Johansen PB; Jensen SE; Rasmussen SN; Dalmark M
    Cancer Chemother Pharmacol; 1984; 13(1):5-8. PubMed ID: 6329539
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics of adriamycin and adriamycinol after intravenous administration of adriamycin to rats with water-deprivation for 48 hours.
    Lee HJ; Lee MG
    Res Commun Mol Pathol Pharmacol; 1997 Jun; 96(3):299-306. PubMed ID: 9261889
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.